Published in Drug Law Weekly, November 20th, 2007
The Company's novel anti-asthmatic compound, RPL554, is now entering a second 28-day experimental inhalation toxicology study in another species in order to demonstrate safety, before moving onto the proof of concept clinical trials early next year.
RPL554 is a long-acting bronchodilator/anti-inflammatory molecule being developed to treat hay fever (rhinitis), asthma and chronic obstructive pulmonary disease. A significant feature of RPL554 is that it does not use steroids or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.